220 related articles for article (PubMed ID: 35954476)
21. [
Lapa C; Schreder M; Schirbel A; Samnick S; Kortüm KM; Herrmann K; Kropf S; Einsele H; Buck AK; Wester HJ; Knop S; Lückerath K
Theranostics; 2017; 7(1):205-212. PubMed ID: 28042328
[TBL] [Abstract][Full Text] [Related]
22. Improved Primary Staging of Marginal-Zone Lymphoma by Addition of CXCR4-Directed PET/CT.
Duell J; Krummenast F; Schirbel A; Klassen P; Samnick S; Rauert-Wunderlich H; Rasche L; Buck AK; Wester HJ; Rosenwald A; Einsele H; Topp MS; Lapa C; Kircher M
J Nucl Med; 2021 Oct; 62(10):1415-1421. PubMed ID: 33579803
[TBL] [Abstract][Full Text] [Related]
23. [
Schwarzenböck SM; Stenzel J; Otto T; Helldorff HV; Bergner C; Kurth J; Polei S; Lindner T; Rauer R; Hohn A; Hakenberg OW; Wester HJ; Vollmar B; Krause BJ
Oncotarget; 2017 Nov; 8(56):95606-95619. PubMed ID: 29221153
[TBL] [Abstract][Full Text] [Related]
24. Chemokine Receptor 4-Targeted 68Ga-Pentixafor PET/CT in Response Assessment of Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma: Comparison to 18F-FDG PET/CT.
Pan Q; Cao X; Luo Y; Li J; Li F
Clin Nucl Med; 2021 Sep; 46(9):732-737. PubMed ID: 34172595
[TBL] [Abstract][Full Text] [Related]
25. Prognostic significance of
Kuyumcu S; Isik EG; Tiryaki TO; Has-Simsek D; Sanli Y; Buyukkaya F; Özkan ZG; Kalayoglu-Besisik S; Unal SN
Ann Nucl Med; 2021 Oct; 35(10):1147-1156. PubMed ID: 34185263
[TBL] [Abstract][Full Text] [Related]
26. Functional nodules in primary aldosteronism: identification of CXCR4 expression with
Gao Y; Ding J; Cui Y; Li T; Sun H; Zhao D; Zhang Y; Huo L; Tong A
Eur Radiol; 2023 Feb; 33(2):996-1003. PubMed ID: 36070092
[TBL] [Abstract][Full Text] [Related]
27. Imaging of Chemokine Receptor 4 Expression in Neuroendocrine Tumors - a Triple Tracer Comparative Approach.
Werner RA; Weich A; Higuchi T; Schmid JS; Schirbel A; Lassmann M; Wild V; Rudelius M; Kudlich T; Herrmann K; Scheurlen M; Buck AK; Kropf S; Wester HJ; Lapa C
Theranostics; 2017; 7(6):1489-1498. PubMed ID: 28529632
[TBL] [Abstract][Full Text] [Related]
28. (68)Ga-Pentixafor-PET/CT for Imaging of Chemokine Receptor 4 Expression in Glioblastoma.
Lapa C; Lückerath K; Kleinlein I; Monoranu CM; Linsenmann T; Kessler AF; Rudelius M; Kropf S; Buck AK; Ernestus RI; Wester HJ; Löhr M; Herrmann K
Theranostics; 2016; 6(3):428-34. PubMed ID: 26909116
[TBL] [Abstract][Full Text] [Related]
29. Immunohistochemical detection of chemokine receptor 4 expression in chronic osteomyelitis confirms specific uptake in 68Ga-Pentixafor-PET/CT.
Bouter Y; Meller B; Sahlmann CO; Wolf BJ; Langer L; Bankstahl JP; Wester HJ; Kropf S; Meller J; Bouter C
Nuklearmedizin; 2018 Sep; 57(5):198-203. PubMed ID: 30267402
[TBL] [Abstract][Full Text] [Related]
30. CXCR4-directed [
Chaman Baz AH; van de Wiel E; Groenewoud H; Arntz M; Gotthardt M; Deinum J; Langenhuijsen J
BMJ Open; 2022 Aug; 12(8):e060779. PubMed ID: 35998969
[TBL] [Abstract][Full Text] [Related]
31. Usefulness of 68 Ga-Pentixafor PET/CT on Diagnosis and Management of Cushing Syndrome.
Ding J; Tong A; Hacker M; Feng M; Huo L; Li X
Clin Nucl Med; 2022 Aug; 47(8):669-676. PubMed ID: 35452014
[TBL] [Abstract][Full Text] [Related]
32. Pentixafor PET/CT for imaging of chemokine receptor 4 expression in esophageal cancer - a first clinical approach.
Linde P; Baues C; Wegen S; Trommer M; Quaas A; Rosenbrock J; Celik E; Marnitz S; Bruns CJ; Fischer T; Schomaecker K; Wester HJ; Drzezga A; van Heek L; Kobe C
Cancer Imaging; 2021 Feb; 21(1):22. PubMed ID: 33579381
[TBL] [Abstract][Full Text] [Related]
33. Clinical Value of
Ding J; Li X; Liu S; Gao Y; Zheng G; Hacker M; Zhang Y; Tong A; Huo L
J Nucl Med; 2024 Jan; 65(1):117-124. PubMed ID: 38050127
[TBL] [Abstract][Full Text] [Related]
34.
Bouter C; Meller B; Sahlmann CO; Staab W; Wester HJ; Kropf S; Meller J
J Nucl Med; 2018 Feb; 59(2):320-326. PubMed ID: 28729430
[TBL] [Abstract][Full Text] [Related]
35. Diagnostic efficacy of C-X-C motif chemokine receptor 4-directed PET/CT in newly diagnosed head and neck squamous cell carcinoma - a head-to-head comparison with [
Zhi Y; Werner RA; Schirbel A; Higuchi T; Buck AK; Kosmala A; Bley TA; Hagen R; Hackenberg S; Rosenwald A; Scherzad A; Gerhard-Hartmann E; Serfling SE
Am J Nucl Med Mol Imaging; 2023; 13(5):208-216. PubMed ID: 38023816
[TBL] [Abstract][Full Text] [Related]
36.
Albano D; Durmo R; Treglia G; Giubbini R; Bertagna F
Clin Lymphoma Myeloma Leuk; 2020 Mar; 20(3):137-146. PubMed ID: 32029397
[TBL] [Abstract][Full Text] [Related]
37. Reduced splenic uptake on
Kraus S; Klassen P; Kircher M; Dierks A; Habringer S; Gäble A; Kortüm KM; Weinhold N; Ademaj-Kospiri V; Werner RA; Schirbel A; Buck AK; Herhaus P; Wester HJ; Rosenwald A; Weber WA; Einsele H; Keller U; Rasche L; Lapa C
Theranostics; 2022; 12(13):5986-5994. PubMed ID: 35966583
[TBL] [Abstract][Full Text] [Related]
38. [
Li X; Yu W; Wollenweber T; Lu X; Wei Y; Beitzke D; Wadsak W; Kropf S; Wester HJ; Haug AR; Zhang X; Hacker M
Eur J Nucl Med Mol Imaging; 2019 Jul; 46(8):1616-1625. PubMed ID: 31004184
[TBL] [Abstract][Full Text] [Related]
39. 68Ga-Pentixafor PET/MRI for Treatment Response Assessment in Mantle Cell Lymphoma: Comparison Between Changes in Lesion CXCR4 Expression on PET and Lesion Size and Diffusivity on MRI.
Mayerhoefer ME; Raderer M; Weber M; Lamm W; Kiesewetter B; Hacker M; Nics L; Schmitl S; Leithner D; Wester HJ; Haug A
Clin Nucl Med; 2023 Jul; 48(7):557-562. PubMed ID: 37272977
[TBL] [Abstract][Full Text] [Related]
40. [Hybrid imaging in lymphoma].
Mayerhöfer ME; Haug A
Radiologe; 2020 May; 60(5):376-385. PubMed ID: 32296856
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
